Clinical Trials Sponsored by AstraZeneca

Total 4361 results

AstraZeneca
AstraZeneca K.K.

Active, not recruiting

A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis (FORTUNA)

Nonalcoholic Steatohepatitis

United States, Italy, Thailand, Germany, Korea, Republic of, Turkey, Vietnam, China, Malaysia, Taiwan, Hong Kong, Chile, Spain, Japan, Mexico, Brazil, Argentina, India, Singapore, Philippines, Peru, Colombia
AstraZeneca
AstraZeneca K.K.

Active, not recruiting

A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia (PURSUIT)

Dyslipidemia

Czechia, United States, Slovakia, Canada, Spain, Hungary, Japan, Denmark
AstraZeneca

Recruiting

Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780

Hepatic Impairment

United States
AstraZeneca

Not yet recruiting

Real-world Study Assessing Efficacy of TezepeLumaB in Patients With Severe Asthma Regardless of Phenotype in Russia (ELBRUS)

Severe Asthma

Russian Federation
AstraZeneca

Not yet recruiting

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies (Soundtrack-E)

Chronic Lymphocytic Leukaemia | Large B-cell Lymphoma | B-cell Non-Hodgkin Lymphoma | Mantle-cell Lymphoma | Small Lymphocytic Leukaemia
AstraZeneca

Not yet recruiting

A Study to Investigate Multiple Ascending Doses of AZD5004 in Healthy Participants

Healthy Participants

United States
AstraZeneca

Recruiting

A Study to Investigate the Relative Bioavailability of AZD8630 Following a Device and Formulation Transition in Healthy Participants.

Healthy Participants

United States
AstraZeneca

Recruiting

Clinical& Demographic Profiles of patIents With unControllEd Asthma in Russia: Multi-center oBsErvational ReGistry Study (ICEBERG)

Uncontrolled Asthma

Russian Federation
AstraZeneca

Recruiting

Phase I PK Study of Budesonide/Albuterol Delivered From PT027 in Healthy Chinese Participants. (PUTUO)

Healthy Volunteer

China
AstraZeneca

Recruiting

NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations (NAUTIC)

Non-squamous Metastatic Non-Small-Cell Lung Carcinoma

Germany
AstraZeneca

Recruiting

Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR) (CORSAR)

Severe Asthma

Russian Federation
AstraZeneca

Recruiting

A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma (BAIYUN)

Asthma

China
AstraZeneca

Recruiting

Patient Characteristics, Treatment Patterns and Outcomes of Patients Enrolled in the Tezepelumab Patient Access Programme; a Retrospective, Observational Medical Chart Review Conducted in UK Severe Asthma Centres (TPAP)

Severe Asthma

United Kingdom
AstraZeneca

Recruiting

A Randomised, Double-blind, Parallel Group, Placebo Controlled, 4-Week, Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma (ARTEMISIA)

Asthma

United Kingdom, Denmark, Spain, Germany, Canada
AstraZeneca

Not yet recruiting

A PROSPECTIVE, MULTI-CENTER, PHASE 4 STUDY TO ASSESS THE SAFETY OF TRASTUZUMAB DERUXTECAN, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE IN INDIAN PATIENTS WITH UNRESECTABLE OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED A PRIOR ANTI-HER2-BASED REGIMEN (STRIDE)

BREAST CANCER
AstraZeneca

Recruiting

A Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In China (PRESENT)

Moderate-to-Severe Asthma

China
AstraZeneca

Recruiting

A Non-interventional, Prospective Study With Benralizumab (AIR POWER)

Asthma, Bronchial

Germany
AstraZeneca

Recruiting

Hereditary Transthyretin Amyloidosis Polyneuropathy in Patients With Carpal Tunnel Syndrome in Russia (LOCUS)

Carpal Tunnel Syndrome | Amyloidosis | Polyneuropathy | Hereditary Transthyretin Amyloidosis

Russian Federation
AstraZeneca

Recruiting

A Study to Investigate the Safety and Pharmacokinetics of AZD6793 in Healthy Japanese and Chinese Participants

Healthy Participants

United States
AstraZeneca

Recruiting

OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis (OverTTuRe)

ATTR Amyloidosis

Spain, China, United States, Japan, Sweden, United Kingdom, Denmark, Germany
AstraZeneca

Recruiting

Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease (MIRO-CKD)

Chronic Kidney Disease

Spain, United States, Italy, Vietnam, Bulgaria, China, Japan, Taiwan, Brazil, Malaysia, Poland, Turkey, Canada, Austria, United Kingdom, Chile
AstraZeneca

Recruiting

A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension

Uncontrolled Hypertension

United States
AstraZeneca

Recruiting

Real-World Outcomes in COPD Patients Starting Trixeo (Budesonide/Glycopyrronium/Formoterol) in Spain. (ORESTES)

Chronic Obstructive Pulmonary Disease (COPD)

Spain
AstraZeneca

Recruiting

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants

Healthy Participants Study

United States
AstraZeneca

Recruiting

REACT - REAl Care for AsThma - A Disease Study to Identify Patients With Severe Uncontrolled Asthma (REACT-Asthma)

Asthma, Bronchial

Germany
AstraZeneca

Recruiting

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)

COPD (Chronic Obstructive Pulmonary Disease)

France, United Kingdom, Denmark, Italy, Spain, United States, Canada, Argentina, Japan, Colombia, Germany, Peru, Brazil, China, India, Thailand, Austria, Serbia, Malaysia, Philippines, Poland, Taiwan, Greece, Norway, Sweden, Mexico, Romania, Korea... and more
AstraZeneca

Recruiting

Study of AZD0754 in Participants With Metastatic Prostate Cancer (APOLLO)

Metastatic Prostate Cancer

United States, Australia
AstraZeneca

Recruiting

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations (NEOLA)

Lung Cancer

Israel, Spain, China, Korea, Republic of, Vietnam, India, Taiwan, Thailand, United States, Turkey
AstraZeneca

Recruiting

Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD (LOOP)

Non-Small Cell Lung Cancer

United States
AstraZeneca

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (CYCAD-1)

ER+ HER2- Advanced Breast Cancer | High-grade Serous Ovarian Cancer (HGSOC)

United States, United Kingdom, Korea, Republic of, Spain, Australia
AstraZeneca

Recruiting

A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants

Healthy Participants

United States
AstraZeneca

Recruiting

NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients (iRetroBC)

HER2-negative

Dominican Republic, Panama, India, Brazil, Thailand, Indonesia, Malaysia, Mexico, Philippines, Singapore, Vietnam
AstraZeneca

Recruiting

Non-alcoholic Steatohepatitis Registry Platform Study

NASH With Fibrosis

China
AstraZeneca

Recruiting

HER2 TREAT Study: Retrospective Study to Estimate the Prevalence of HER2-low in Unresectable and/or Metastatic Breast Cancer Patients Who Progress on Anti-Cancer Therapy Identified as HER2-Negative From Patient Medical Records in The Gulf Cooperation Council

Breast Cancer | Breast Neoplasms | Breast Carcinoma | Genes | HER2

Kuwait, Saudi Arabia, United Arab Emirates, Qatar
AstraZeneca

Recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants

Rheumatoid Arthritis

United Kingdom, Canada
AstraZeneca

Recruiting

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) (ARTEMIDE-Bil01)

Biliary Tract Cancer

United States, France, Spain, Korea, Republic of, Belgium, Canada, Italy, Germany, United Kingdom, Brazil, China, Japan, Taiwan, Thailand, Australia, Hong Kong, Poland, India, Denmark, Turkey, Norway
AstraZeneca

Recruiting

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States, Spain, Australia, Canada, Germany, China, France, Japan
AstraZeneca

Recruiting

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (eVOLVE-Meso)

Unresectable Pleural Mesothelioma

United States, Australia, Netherlands, Korea, Republic of, Belgium, Germany, Italy, Poland, Canada, Norway, Japan, United Kingdom, Spain, China, Taiwan, France, South Africa, Brazil, Switzerland, Turkey, Denmark
AstraZeneca

Recruiting

Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)

Chronic Kidney Disease With High Proteinuria

China, United States, Netherlands, Poland, Germany, Argentina, Denmark, Japan, Norway, Spain, Sweden, Bulgaria, France, India, Malaysia, Taiwan, Thailand, Vietnam, Italy, Mexico, Turkey, Israel, Brazil, United Kingdom, South Africa, Austria, Korea, Republic... and more
AstraZeneca

Recruiting

Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease

Crohn's Disease

Sweden
AstraZeneca

Recruiting

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (EMERALD-Y90)

Hepatocellular Carcinoma (HCC)

United States
AstraZeneca
AstraZeneca

Recruiting

A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil (EDUR-BRA)

Extensive-stage Small-cell Lung Cancer

Brazil
AstraZeneca

Recruiting

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL (ACRUE)

Diffuse Large B-Cell Lymphoma

United States, Korea, Republic of, Brazil, Puerto Rico
AstraZeneca

Recruiting

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) (DAISY)

Systemic Sclerosis | Scleroderma

China, United States, Italy, Mexico, Canada, Hungary, Germany, Spain, Belgium, Netherlands, Japan, Poland, Korea, Republic of, Vietnam, France, Austria, Israel, Malaysia, Turkey, United Kingdom, South Africa, India, Romania
AstraZeneca

Recruiting

A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian Federation (OVARD)

Ovarian Cancer

Russian Federation
AstraZeneca

Recruiting

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants (SLE)

Systemic Lupus Erythematosus

China, Italy, United States, Portugal, Spain, Turkey, Mexico, United Kingdom, Colombia, France, Germany, Brazil, Canada, Argentina, Poland, South Africa
AstraZeneca

Recruiting

TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)

Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)

Japan
AstraZeneca

Recruiting

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR)

NSCLC

United States, United Kingdom, Korea, Republic of, Italy, Hungary, Spain, France, Brazil, Canada, Japan, Taiwan, Germany, Austria, India, Peru, Poland, Vietnam, Sweden, Bulgaria, Greece, Mexico, China, Turkey, Denmark
AstraZeneca

Recruiting

LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)

Breast Cancer

Japan
AstraZeneca

Not yet recruiting

A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs (EXCEED)

Pancreatic Cancer

3

Subscribe